Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.
  • Nationwide storytelling movement to showcase diverse voices of the type 1 diabetes community, including internationally recognized stars Usher, Robin Arzón, and Adam Schefter, to share experiences and encourage people to get screened
  • The 1 Pledge movement commences with surround-sound event in New York City's Times Square; continues throughout the year with events and social storytelling
  • Screening for type 1 diabetes can detect the disease before noticeable symptoms arise1; people can pledge to get themselves and their family screened at The1Pledge.com

BRIDGEWATER, N.J., Nov. 1, 2023 /PRNewswire/ -- Sanofi, a leader in diabetes care, today launched "The 1 Pledge" movement, a nationwide education campaign urging families to get screened for type 1 diabetes so that those who will eventually be affected by the disease can begin to prepare as soon as possible.

"The 1 Pledge" movement will be driven by widely known celebrities, including musician and philanthropist Usher Raymond IV, whose child was diagnosed with type 1 diabetes at age 6.

Type 1 diabetes can be a lifechanging diagnosis that can be detected before the onset of symptoms,1 which can be diagnosed at any age but usually develops and is diagnosed during childhood and young adulthood.2 Approximately 1.45 million Americans have type 1 diabetes3 and many families with children who have type 1 diabetes say that knowing about the disease as early as possible allows time for important education, preparation and coaching.1

USHER
Award-winning singer, songwriter, actor, entrepreneur, and philanthropist
"Since the day my child was diagnosed with type 1 diabetes, the condition is something I never stop thinking about. Had we detected my child's type 1 diabetes before their diagnosis it could have given us valuable time to prepare. My child's bravery inspires me every day and my hope in partnering with Sanofi is to inspire other families in this important work. Do not wait until you see symptoms. Pledge to screen for type 1 diabetes today so you can prepare for what could come."

Other participants include Robin Arzón, Vice President of Fitness Programming and Head Instructor at Peloton and a type 1 diabetes patient herself; and journalist Adam Schefter, whose wife Sharri Maio lives with type 1 diabetes and has been a longtime advocate for raising awareness around the disease.

Robin Arzón
Vice President of Fitness Programming and Head Instructor at Peloton, ultramarathoner and best-selling author
"I was diagnosed with type 1 diabetes in my early thirties, and in an instant my life and daily routine changed. A diagnosis like this can be scary, even shocking, for so many and their families, but I believe in the power of education and awareness. The more we know, the more we can do. The 1 Pledge is very personal for me, and I encourage everyone to screen for type 1 diabetes."

Adam Schefter 
Sports journalist
"My wife Sharri was diagnosed with type 1 diabetes over 20 years ago. She is the rock of our family, even while navigating this condition. We have been advocating for awareness around type 1 diabetes for nearly as many years as she has been living with diabetes. I built my career on the power of early knowledge and we joined this movement because we believe that a decision today to screen for type 1 diabetes could help change you or your family's future. That's also why we have had our daughter screened for type 1. We know from our experience that our children are at a higher risk of developing type 1 diabetes because there is familial history, so we are pledging to take action. Join us in this powerful movement today." 

By using personal stories, these celebrities aim to share the importance of screening, education and preparation for type 1 diabetes. Patients, caregivers and other influencers are slated to add their voices to the effort as the movement accelerates.

Olivier Bogillot
Head of U.S. General Medicines, Sanofi
"For many families, a type 1 diabetes diagnosis is sudden and life changing. With The 1 Pledge campaign, our aim is to raise awareness that type 1 diabetes can be detected early and that screening is available and may help to better prepare families to manage the disease. Sanofi remains committed to help people living with diabetes and to bring innovation to this community."

Type 1 diabetes is an autoimmune disease in which the pancreas does not make enough insulin and people with type 1 diabetes eventually rely on insulin.4 Type 1 diabetes can present itself in first- and second-degree relatives – in fact, if someone in a family has type 1 diabetes, it is approximately up to 15 times more likely to manifest in someone else in the family5 – but this is not always the case: approximately 90% of people who develop type 1 diabetes do not have a family history.6 Type 1 diabetes also frequently presents with life-threatening complications.7 Early screening is important because blood tests can detect autoantibodies associated with type 1 diabetes before serious crises occur.1 While type 1 diabetes can't be prevented,3 taking the step to screen may give people more time to prepare.

Making the decision to get screened and get one's family screened could give families time to get educated and be prepared early. People can pledge to get screened for type 1 diabetes today at The1Pledge.com, and follow the movement on social media using #ScreenforType1. Sanofi encourages people interested in learning more about screening or type 1 diabetes to speak to their doctor.

Usher, Robin Arzón, Adam Schefter and the other social media personalities that are participating are paid spokespeople for Sanofi.

About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Evan Berland | + 1 215 432 0234 | evan.berland@sanofi.com 

Investor Relations
Eva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.com
Arnaud Delépine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.com
Corentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.com
Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com
Priya Nanduri | +1 617 764 6418 | priya.nanduri@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole.  The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2022. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

References

  1. Beyond Type 1. Screening for Type 1 Diabetes. https://beyondtype1.org/screening-for-type-1-diabetes/. Accessed October 2023.
  2. CDC. What is Type 1 Diabetes? https://www.cdc.gov/diabetes/basics/what-is-type-1-diabetes.html. Accessed October 2023.
  3. Beyond Type 1. Type 1 Diabetes Statistics. https://beyondtype1.org/type-1-diabetes-statistics. Accessed October 2023.
  4. JDRF. Diabetes 101. https://www.jdrf.org/t1d-resources/about/. Accessed October 2023.
  5. Van Belle T, et al. Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies. Physiological Reviews. 2011;91:79-118. https://doi.org/10.1152/physrev.00003.2010
  6. Steck A & Rewers M. Genetics of Type 1 Diabetes. Clinical Chemistry. 2011;57(2):176-185. https://doi.org/10.1373/clinchem.2010.148221.
  7. Nakhla M, et al. Diabetic Ketoacidosis at the Time of Diagnosis of Type 1 Diabetes in Children. JAMA Pediatrics. 2021;175(5):518-520. https://doi.org/10.1001/jamapediatrics.2020.5512.

SOURCE Sanofi